Next Article in Journal
A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier
Previous Article in Journal
A Miniaturized Extruder to Prototype Amorphous Solid Dispersions: Selection of Plasticizers for Hot Melt Extrusion
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(2), 59;

Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses

Institute of Molecular Biology and Genetics, National Academy Science of Ukraine, 03680 Kyiv, Ukraine
Pasteur Institute of Epidemiology and Microbiology, 14 Mira str, 197101 St. Petersburg, Russia
Department of Infectious Diseases and Epidemiology, I. Ya. Horbachevsky Ternopil State Medical University, 46002 Ternopil, Ukraine
Author to whom correspondence should be addressed.
Received: 12 March 2018 / Revised: 30 April 2018 / Accepted: 14 May 2018 / Published: 19 May 2018
Full-Text   |   PDF [1475 KB, uploaded 19 May 2018]   |  


Oligoribonucleotides-D-mannitol (ORNs-D-M) complexes possess antiviral, anti-inflammatory, and immunomodulatory actions. The aim of the present study was to evaluated an antiviral effect of ORNs-D-M against parainfluenza virus type 3 (PIV3); influenza CA709, PR834; avian influenza virus H5N2 (AIV) in vitro by a TCID50; hemadsorption and neuraminidase activity assays; and clinical efficiency of ORNs-D-M in patients with acute respiratory infections (ARIs) of various etiologies by PCR assay and AmpliSens test systems. It was observed that ORNs-D-M have an antiviral activity against the influenza CA709, PR834, PIV3, and AIV in vitro. The injectable dosage form of ORNs-D-M was shown to have a stronger antiviral effect compared to capsule form. It was also detected that the injectable form of ORNs-D-M significantly reduced the neuraminidase activity of influenza PR834. A complex treatment of patients with ORNs-D-M had a positive effect on the course of the disease, it accelerated patients’ recovery. Treatment with ORNs-D-M caused eradication of adeno- and influenza viruses in patients with ARI. This drug contributed to significant decrease in duration of febrile period and cough. Comprehensive treatment with ORNs-D-M improved the disease clinical findings significantly. Collectively, these results suggested that ORNs-D-M may be used at co-infection with influenza and other respiratory viruses as a medical antiviral drug. View Full-Text
Keywords: acute respiratory infections; oligoribonucleotides-D-mannitol complexes acute respiratory infections; oligoribonucleotides-D-mannitol complexes

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Melnichuk, N.; Zarubaev, V.; Iosyk, I.; Andreychyn, M.; Semernikova, L.; Tkachuk, Z. Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses. Pharmaceutics 2018, 10, 59.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top